CD19CAR T-cell therapy for relapsed / refractory B-cell acute lymphoblastic leukemia

Abstract

This disclosure relates to CD19 CAR-T cell products and methods for treating relapsed or refractory CD19+ hematological malignancies. Specifically, autologous CD19 CAR-T cells for use in a method for treating relapsed or refractory CD19+ hematological malignancies in a patient, comprising the step of administering autologous CD19 CAR-T cells to the patient, wherein the patient has a blast cell count of 20% or less in the bone marrow (BM), and the patient is given approximately 100 × 10⁶ cells. 6 The first dose contains 10 CAR T cells and approximately 310 × 10⁶ 6 A second dose containing 10 CAR T cells is administered, and / or if the patient has a greater than 20% blast cell presence in the bone marrow (BM), the patient is given approximately 10 × 10 6 The first dose contains 10 CAR T cells and approximately 400 × 10 6 Autologous CD19 CAR-T cells are provided, to which a second dose containing 100 CAR T cells is administered.

Images